2Roberto C, Femando P, Paolo T, et al .The heparins and cancer:review of clinical trials and biological properties. Vascular Med,2004,9:205-213. 被引量：1
3Yu MK, Lee DY, Kim YS, et al. Antiangiogenic and Apoptotic Properties of a Novel Amphiphilic Folate-Heparin-Lithocholate Derivative Having Cellular Internality for Cancer Therapy. Pharma Res ,2007,24:705-714. 被引量：1
4Abe R, Fujita Y, Yamagishi S, et al. Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini Rev Med Chem, 2007, 7:649-661. 被引量：1
5Suhardja A, Hoffman H. Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microsc Res Tech, 2003, 60:70-75 被引量：1
6Pisano C, Aulicino C, Vesci L, et al. low-molecular-weight glycolsplit heparin as an antiangiogenic VEGF antagonist. Glycobiology, 2005, 15 : 1C- 6C. 被引量：1
7Casu B, Guerrini M, Guglieri S, et al. Undersulfated and glycol-split heparins endowed with antiangiogenic activity. Med Chem,2004,47:838-848. 被引量：1
8Norrby K. 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis.Int J Exp Pathol,2000, 81 : 191-198. 被引量：1
9Bjornsson TD, Schneider DE, Hecht AR, et al. Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo dispositon. J Pharmacol Exp Ther, 1998, 245:804-808. 被引量：1
10Thourani VH, Brar SS, Kennedy TP, et al. Nonanticoagulant heparin inhibits NF-kB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol,2000,278 : H2084-2093. 被引量：1
